**Abstract**

**Objective**: Aim of the paper is to assess the therapeutic efficacy and tolerability of paliperidone palmitate long-acting injectable antipsychotic in first-episode adolescent schizophrenic patients. The management of patients with a first-episode of psychosis remains a challenge. Treating patients with paliperidone palmitate avoids the issue of non-compliance.

**Methods:** The research included 18 patients aged 15 to 17 years who were diagnosed in accordance with the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. All patients were assessed six times over twelve months using the following clinical scales: Positive and Negative Syndrome Scale, Clinical Global Impression - Severity and Improvement Scale, Personal and Social Performance Scale. Primary safety measures included incidence of adverse events. Patients and their families have given consent for the treatment.

**Results:** In this twelve-month analysis all patients with first-episode psychosis achieved remission, which was significantly associated with early treatment response. There were no hospitalizations during this period. Patients demonstrated a trend towards greater improvement in function, health status and productivity.

**Conclusion:** All doses of once-monthly paliperidone palmitate were efficacious and generally tolerated. Earlier application of paliperidone palmitate resulted in no relapse, better reaction to therapy, achieving remission and full recovery.
